Neuren granted Type B Meeting with FDA for Rett syndrome
Filed with ASX · · 1 page · English
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- Appendix 3B
- Neuren secures funding for key activities for Rett syndrome
- Response to ASX Price Query
- Trading Halt
- Investor presentation, 2 June 2017
Later from Neuren Pharmaceuticals
- Notice of special meeting of shareholders
- Neuren Pharmaceuticals reports 2017 half-year results
- Results of Meeting
- Notice under section 708A(5)(e) of the Corporations Act
- Change of Director's Interest Notice
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals